Eccentric overload muscle damage is attenuated by a novel angiotensin- (1-7) treatment.
No Thumbnail Available
Date
2018
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
The development of new strategies to attenuate exercise-induced muscle damage may be helpful for training regimens. The
aim of this study was to determine whether a oral formulation of
angiotensin Ang-(1-7)[HPβCD/Ang-(1-7)] is effective to reduce
pain, and muscle damage markers after eccentric-overload exercise. HPβCD (Placebo) and HPβCD/Ang-(1-7) (Ang-(1-7) group
were treated for 7 days (one capsule/day). The pain was measured by visual analogue scale, maximal strength (MS) using force
platform. Blood samples were collected for cytokines and creatine kinase (CK) analysis. The Ang-(1-7)-treated group reported
less pain immediately (3.46± 0.64 vs. placebo 3.80± 0.77 cm)
and 24h after exercise (3.07±0.71 vs. 3.73±0.58cm placebo)
and higher MS at 24h (24±12N) and 48h (30±15N) vs. placebo
(-8 ± 9 N and -10 ± 9 N). The CK for Ang-(1-7) (0.5 ± 0.1 and
0.9±0.2 U/L) were lower at 48 and 72h vs. placebo (fold changes of 1.7±0.5 and 1.5±0.3 U/L). The TNF-α level was lower in the
treated group post-exercise (38 ± 2.5 pg/ml) vs. placebo
(45 ± 2.9 pg/ml) but no significant changes were observed for
IL-6 and IL-10. Our data indicate that treatment with Ang-(1-7)
may attenuate pain, some of the muscle damage markers and
improves performance following eccentric exercise.
Description
Keywords
Physical performance, Muscular damage
Citation
OLIVEIRA, L. K. B. et al. Eccentric overload muscle damage is attenuated by a novel angiotensin- (1-7) treatment. International Journal of Sports Medicine, v. 39, n. 10, p. 743-748, 2018. Disponível em: <https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-0633-8892>. Acesso em: 20 fev. 2019.